- $722.30m
- $513.05m
Brief: Annexon To Report Archer Phase 2 Trial Results In Geographic Atrophy At ASRS 2023
U.S. RESEARCH ROUNDUP- Kenvue, Universal Health Services, Workday
U.S. STOCKS ON THE MOVE-Ralph Lauren, American Airlines, Illumina
U.S. STOCKS ON THE MOVE-NVIDIA, e.l.f. Beauty, Dish Network
Annexon falls as brokerages cut PT after eye disease therapy fails mid-stage trial
Annexon falls as brokerages cut PT after eye disease therapy fails mid-stage trial
U.S. RESEARCH ROUNDUP-Annexon, Nvidia, Southwestern Energy
Annexon slumps as eye disease therapy fails in mid-stage study
Brief: Annexon Topline Data From Archer Phase 2 Trial Of ANX007 In Geographic Atrophy Demonstrated Statistically Significant, Dose-Dependent Preservation Of Visual Function
Brief: Annexon Reports First Quarter 2023 Financial Results
Annexon Inc reports results for the quarter ended in March - Earnings Summary
Annexon Inc expected to post a loss of 52 cents a share - Earnings Preview
Brief: Annexon As Of March 10 Had Deposit Accounts With SVB Of About $0.5 Mln
Brief: Annexon Reports Fourth Quarter And Year-End 2022 Financial Results
Annexon Inc expected to post a loss of 53 cents a share - Earnings Preview
Brief: Annexon Appoints Dr. Rick Artis As Chief Scientific Officer
U.S. RESEARCH ROUNDUP-Caterpillar, Endava, Harpoon Therapeutics
Annexon Inc reports results for the quarter ended in September - Earnings Summary
Brief: Annexon Reports Third Quarter 2022 Financial Results